7,8-二羟基-2,3,4,5-四氢-2-苯并氮杂卓,氢溴酸盐

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 中文名称: 7,8-二羟基-2,3,4,5-四氢-2-苯并氮杂卓,氢溴酸盐
• 中文别名: O-乙酰基-L-高丝氨酸盐酸盐
• 英文名称: 2,3,4,5-tetrahydro-1H-2-benzazepine-7,8-diol hydrobromide
• 英文别名: 2,3,4,5-tetrahydro-1H-2-benzazepin-2-ium-7,8-diol;bromide
• 化学式: BrH*C₁₀H₁₃NO₂
• 分子量: 260.131
• InChiKey: QELFRECJCWLACD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.71
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  52.5
• 氢给体数：
  4
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-硫代异氰酸辛酯 、 7,8-二羟基-2,3,4,5-四氢-2-苯并氮杂卓,氢溴酸盐 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 7,8-dihydroxy-N-octyl-1,3,4,5-tetrahydro-2-benzazepine-2-carbothioamide
  参考文献：
  名称：

  SAR studies of capsazepinoid bronchodilators 3: The thiourea part (coupling region) and the 2-(4-chlorophenyl)ethyl moiety (C-region)

  摘要：

  Certain derivatives and analogues of capsazepine are potent in vitro inhibitors of bronchoconstriction in human small airways. During an investigation of the dependency of the potency on the structural features of the capsazepinoids in the thiourea moiety (coupling region) and the 2-(4-chlorophenyl)ethyl moiety (Gregion), it was revealed that capsazepinoids with a thiourea or an amide link between the B-ring and the Gregion in general have a good bronchorelaxing activity, while urea is a less attractive choice. Further, it was shown that 1,2,3,4-tetrahydroisoquinolines with a 2-(phenyl)ethyl derivative as the C-region are considerably more potent than those with an octyl group, while 2,3,4,5-tetrahydro-1H-2-benzazepines were found to be more insensitive to the nature of the Gregion. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.11.056
• 作为产物：
  描述：

  N-benzyl-3-(3-hydroxy-4-methoxyphenyl)propylamine 在 甲烷磺酸 、 palladium 10% on activated carbon 、 氢溴酸 、 氢气 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 16.0h， 生成 7,8-二羟基-2,3,4,5-四氢-2-苯并氮杂卓,氢溴酸盐
  参考文献：
  名称：

  TRPV1通道的光学控制

  摘要：

  用光控制疼痛：TRPV1通道介导对有害热量的反应，并可以被辣椒的主要成分辣椒素激活。新型偶氮苯光电开关可用于TRPV1的光学控制。这些化合物中的一种以光依赖的方式拮抗辣椒素，表明可光转换的拮抗剂和激动剂可以协同使用以调节离子通道活性。

  DOI：

  10.1002/anie.201302530

文献信息

• Bronchorelaxing compounds
  申请人：Skogvall Staffan

  公开号：US20050165004A1

  公开（公告）日：2005-07-28

  A compound of the general formula (I) including its pharmaceutically acceptable acid addition salts wherein A is CHR 9 , wherein R 9 is H, C 1 -C 6 alkyl; n is 1-3; B is CHR 10 , wherein R 10 is H, C 1 -C 6 alkyl; m is 1 or 2; D is O or S or optionally NR 16 , wherein R 16 is H, C 1 -C 6 alkyl or C 2 -C 6 acyl; E is CR 11 R 12 or NR 13 , wherein R 11 and R 12 are, independent of each other, H or C 1 -C 6 alkyl, R 13 is H or C 1 -C 6 alkyl; F is C 1 -C 18 alkyl which may be mono- or di-unsaturated and/or substituted, is useful in treating and preventing pulmonary disease characterized by bronchoconstriction. Also disclosed are pharmaceutical compositions comprising the compound and methods for their manufacture.

  通用式（I）的化合物及其药学上可接受的酸盐包括其中 其中A为CHR 9 ，其中R 9 为H，C 1 -C 6 烷基；n为1-3；B为CHR 10 ，其中R 10 为H，C 1 -C 6 烷基；m为1或2；D为O或S或可选地为NR 16 ，其中R 16 为H，C 1 -C 6 烷基或C 2 -C 6 酰基；E为CR 11 R 12 或NR 13 ，其中R 11 和R 12 独立地为H或C 1 -C 6 烷基，R 13 为H或C 1 -C 6 烷基；F为C 1 -C 18 烷基，可以是单烯或双烯和/或取代的，用于治疗和预防以支气管痉挛为特征的肺部疾病。还公开了包含该化合物的药物组合物及其制备方法。
• [EN] BRONCHORELAXING COMPOUNDS<br/>[FR] COMPOSES BRONCHO-RELACHANTS
  申请人：RESPIRATORIUS AB

  公开号：WO2005070887A1

  公开（公告）日：2005-08-04

  A compound of the general formula (I) including its pharmaceutically acceptable acid addition salts formula (I) wherein A is CHR9, wherein R9 is H, C1-C6 alkyl;n is 1-3; B is CHR10, wherein R10 is H, C1-C6 alkyl; m is 1 or 2; D is O or S; E is CR11R12 or NR13, wherein R11 and R12 are, independent of each other, H or C1-C6 alkyl, R13 is H or C1-C6 alkyl; F is C1-C18 alkyl or R4-R7 cycloalkyl, which may be mono- or di-unsaturated and/or substituted, is useful in treating and preventing pulmonary disease characterized by bronchoconstriction; also disclosed is a pharmaceutical composition comprising the compound of formula (I), a pharmaceutical carrier and, optionally, an anti-asthmatic, a method for its manufacture, and a method for treating or preventing such disease.

  通式（I）的化合物及其药学上可接受的酸加合盐，其中A为CHR9，其中R9为H，C1-C6烷基；n为1-3；B为CHR10，其中R10为H，C1-C6烷基；m为1或2；D为O或S；E为CR11R12或NR13，其中R11和R12独立地为H或C1-C6烷基，R13为H或C1-C6烷基；F为C1-C18烷基或R4-R7环烷基，可以是单烯或双烯和/或取代的，用于治疗和预防以支气管收缩为特征的肺部疾病；还公开了包含通式（I）的药物组合物、药物载体和可选的抗哮喘药、其制造方法以及治疗或预防该疾病的方法。
• SAR studies of capsazepinoid bronchodilators. Part 1: The importance of the catechol moiety and aspects of the B-ring structure
  作者：Marı´a F. Dalence-Guzmán、Magnus Berglund、Staffan Skogvall、Olov Sterner

  DOI：10.1016/j.bmc.2007.11.055

  日期：2008.3

  Capsazepine as well as its derivatives and analogues are general inhibitors of constriction of human small airways. From a systematic variation of the capsazepine structure, divided into four regions, SARs were established. This part concerns the catechol moiety of the A-ring as well as the 2,3,4,5-tetrahydro-1H-2-azepine moiety (the B-ring) of capsazepine. It is revealed that a conformational constrain (as a fused ring) is important and that compounds with a six-membered B-ring (as a 1,2,3,4-tetrahydroisoquinoline) in general are more potent than the corresponding isoindoline, 2,3,4,5 -tetrahydro-1H-2-benzazepi ne and 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives. (C) 2007 Elsevier Ltd. All rights reserved.
• The Discovery of Capsazepine, the First Competitive Antagonist of the Sensory Neuron Excitants Capsaicin and Resiniferatoxin
  作者：Christopher S. J. Walpole、Stuart Bevan、Guenter Bovermann、Johann J. Boelsterli、Robin Breckenridge、John W. Davies、Glyn A. Hughes、Iain James、Lukas Oberer、Janet Winter、Roger Wrigglesworth

  DOI：10.1021/jm00039a006

  日期：1994.6.1

  Capsaicin and resiniferatoxin are natural products which act specifically on a subset of primary afferent sensory neurons to open a novel cation-selective ion channel in the plasma membrane. These sensory neurons are involved in nociception, and so, these agents are targets for the design of a novel class of analgesics. Although synthetic agonists at the capsaicin receptor have been described previously, competitive antagonists at this receptor would be interesting and novel pharmacological agents. Structure-activity relationships for capsaicin agonists have previously been rationalized, by ourselves and others, by dividing the capsaicin molecule into three regions-the A (aromatic ring)-, B (amide bond)-, and C (hydrophobic side chain)-regions. In this study, the effects on biological activity of conformational constraint of the A-region with respect to the B-region are discussed. Conformational constraint was achieved by the introduction of saturated ring systems of different sizes. The resulting compounds provided agonists of comparable potency to unconstrained analogues as well as a moderately potent antagonist, capsazepine. This compound is the first competitive antagonist of capsaicin and resiniferatoxin to be described and is active in various systems, in vitro and in vivo. It has recently attracted considerable interest as a tool for dissecting the mechanisms by which capsaicin analogues evoke their effects. NMR spectroscopy and X-ray crystallography experiments, as well as molecular modeling techniques, were used to study the conformational behavior of a representative constrained agonist and antagonist. The conformation of the saturated ring contraint in the two cases was found to differ markedly, dramatically affecting the relative disposition of the A-ring and B-region pharmacophores. In agonist structures, the A- and B-regions were virtually coplanar in contrast to those in the antagonist, in which they were approximately orthogonal. A rationale for agonist and antagonist activity at the capsaicin receptor is proposed, based on the consideration of these conformational differences.
• A Facile and Practical Synthesis of Capsazepine, a Vanilloid Receptor Antagonist
  作者：Jeewoo Lee、Jiyoun Lee

  DOI：10.1080/00397919908085886

  日期：1999.12.1

  A facile and practical synthesis of capsazepine, a vanilloid receptor antagonist, has been accomplished from isovanillin in 8 steps via an efficient intramolecular Mannich cyclization.